Now Playing
Opinion|Videos|December 19, 2025
TRANSFORM + Long-Term Follow-Up ASH 2025 Insights: Durability, Survival, and Safety Updates
Panelists discuss long-term outcomes from the TRANSFORM study evaluating liso-cel in second-line relapsed/refractory LBCL. The conversation highlights durability of response, progression-free and overall survival trends, and updated safety findings presented at the American Society of Hematology Annual Meeting 2025. Faculty consider how extended follow-up informs expectations for long-term remission with CAR T therapy.
Advertisement
Episodes in this series
Panelists discuss long-term outcomes from the TRANSFORM study evaluating liso-cel in second-line relapsed/refractory LBCL. The conversation highlights durability of response, progression-free and overall survival trends, and updated safety findings presented at the American Society of Hematology Annual Meeting 2025. Faculty consider how extended follow-up informs expectations for long-term remission with CAR T therapy.
Advertisement
Related to this article
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5